ch
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ๅ‰ๅพ€้ข‘้“ๅœจ Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

ๆ˜พ็คบๆ›ดๅคš

๐Ÿ“ˆ Telegram ้ข‘้“ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ ็š„ๅˆ†ๆžๆฆ‚่งˆ

้ข‘้“ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) ้˜ฟๆ‹‰ไผฏ่ฏญ ่ฏญ่จ€่ต›้“ไธญ็š„ ๆ˜ฏๆดป่ทƒๅ‚ไธŽ่€…ใ€‚็›ฎๅ‰็คพๅŒบ่š้›†ไบ† 13 339 ๅ่ฎข้˜…่€…๏ผŒๅœจ ๅŒปๅญฆ ็ฑปๅˆซไธญไฝๅˆ—็ฌฌ 1 928๏ผŒๅนถๅœจ ๆฒ™็‰น้˜ฟๆ‹‰ไผฏ ๅœฐๅŒบๆŽ’ๅ็ฌฌ 5 694 ไฝใ€‚

๐Ÿ“Š ๅ—ไผ—ๆŒ‡ๆ ‡ไธŽๅขž้•ฟๅŠจๆ€

่‡ช ะฝะตะฒั–ะดะพะผะพ ๅˆ›ๅปบไปฅๆฅ๏ผŒ้กน็›ฎไฟๆŒ้ซ˜้€Ÿๅขž้•ฟ๏ผŒๅธๅผ•ไบ† 13 339 ๅ่ฎข้˜…่€…ใ€‚

ๆ นๆฎ 28 ๅ…ญๆœˆ, 2026 ็š„ๆœ€ๆ–ฐๆ•ฐๆฎ๏ผŒ้ข‘้“ไฟๆŒ็จณๅฎš่ฟ่ฝฌใ€‚่ฟ‡ๅŽป 30 ๅคฉ่ฎข้˜…ไบบๆ•ฐๅ˜ๅŒ–ไธบ 196๏ผŒ่ฟ‡ๅŽป 24 ๅฐๆ—ถๅ˜ๅŒ–ไธบ -18๏ผŒๆ•ดไฝ“่งฆ่พพไป็„ถๅฏ่ง‚ใ€‚

  • ่ฎค่ฏ็Šถๆ€๏ผš ๆœช่ฎค่ฏ
  • ไบ’ๅŠจ็އ (ER)๏ผš ๅนณๅ‡ๅ—ไผ—ไบ’ๅŠจ็އไธบ 27.91%ใ€‚ๅ†…ๅฎนๅ‘ๅธƒๅŽ 24 ๅฐๆ—ถๅ†…้€šๅธธ่ƒฝ่Žทๅพ— 9.87% ็š„ๅๅบ”๏ผŒๅ ่ฎข้˜…่€…ๆ€ป้‡ใ€‚
  • ๅธ–ๅญ่ฆ†็›–๏ผš ๆฏ็ฏ‡ๅธ–ๅญๅนณๅ‡ๅฏ่Žทๅพ— 3 727 ๆฌกๆต่งˆ๏ผŒ้ฆ–ๆ—ฅ้€šๅธธ็ดฏ็งฏ 1 318 ๆฌกๆต่งˆใ€‚
  • ไบ’ๅŠจไธŽๅ้ฆˆ๏ผš ๅ—ไผ—็งฏๆžๅ‚ไธŽ๏ผŒๅ•ๅธ–ๅนณๅ‡ๅๅบ”ๆ•ฐไธบ 36ใ€‚
  • ไธป้ข˜ๅ…ณๆณจ็‚น๏ผš ๅ†…ๅฎน้›†ไธญๅœจ ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ ็ญ‰ๆ ธๅฟƒไธป้ข˜ไธŠใ€‚

๐Ÿ“ ๆ่ฟฐไธŽๅ†…ๅฎน็ญ–็•ฅ

ไฝœ่€…ๅฐ†่ฏฅ้ข‘้“ๅฎšไฝไธบ่กจ่พพไธป่ง‚่ง‚็‚น็š„ๅนณๅฐ๏ผš
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

ๅ‡ญๅ€Ÿ้ซ˜้ข‘ๆ›ดๆ–ฐ๏ผˆๆœ€ๆ–ฐๆ•ฐๆฎ้‡‡้›†ไบŽ 29 ๅ…ญๆœˆ, 2026๏ผ‰๏ผŒ้ข‘้“ๅง‹็ปˆไฟๆŒๆ–ฐ้ฒœๅบฆไธŽ้ซ˜่ฆ†็›–ใ€‚ๅˆ†ๆžๆ˜พ็คบๅ—ไผ—็งฏๆžไบ’ๅŠจ๏ผŒไฝฟๅ…ถๆˆไธบ ๅŒปๅญฆ ็ฑปๅˆซไธญ็š„ๅ…ณ้”ฎๅฝฑๅ“็‚นใ€‚

13 339
่ฎข้˜…่€…
-1824 ๅฐๆ—ถ
+2847 ๅคฉ
+19630 ๅคฉ
ๅธ–ๅญๅญ˜ๆกฃ
ู…ุฑุญุจุง ุงู†ูŠ ุทุงู„ุจุฉ ุตูŠุฏู„ุฉ ุฌุงู…ุนู‡ ุงู„ู…ุดุฑู‚ ุนู†ุฏูŠ ุจุญุซ ูŠุฎุต ุจุฎุงุฎุงุช ุงู„ุฑุจูˆ ูˆ COPD ู…ู…ูƒู† ุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ูˆ ุงู‡ู…ุดูŠ ุฑู‚ู… collaborator code :3 ูˆ ุดูƒุฑุงู‹ https://forms.gle/hFujpBaFvBNf3kNF6

An intramuscular agent, is approved for second line therapy of postmenopausal patients with hormone receptor-positive breast cancer either alone or in combination with targeted therapy? A) Tamoxifen B) Raloxifene C) Toremifene D) pertuzumab E) Fulvestrant ุจู…ุญุงุถุฑุฉ ุงู„ breast cancer ูู‚ุท ุฏูˆุงุก ูˆุงุญุฏ ู…ุฐูƒูˆุฑ ุงู†ู‡ ู†ู†ุทูŠู‡ im ูŠุนู†ูŠ ุจุฏูˆู† ู…ุง ุชูƒู…ู„ ุงู„ุณุคุงู„ ุชุฎุชุงุฑ ูˆุงู†ุช ู…ุบู…ุถ ูˆูƒู„ุงู… ุงู„ุณุคุงู„ ู†ุตุง ู…ู† ุงู„ู…ู„ุฒู…ุฉ ู…ุงูƒูˆ ู…ุนู„ูˆู…ุฉ ู…ู…ูŠุฒุฉ ู…ุฌุฑุฏ ู…ุนู„ูˆู…ุฉ ุฏุฑุฎูŠุฉ ูˆุฒุงุฑูŠ 25 ุฏูˆุฑ 1 #Breast_Cancer

HER2 over expressing MBC, what is the preferred First line therapy?
Anonymous voting

A patient with HER2-positive MBC was initially treated with a combination of pertuzumab, trastuzumab, and a taxane. After months, her disease progressed. Which of the following treatments is most appropriate as second-line HER2- targeted therapy?
Anonymous voting

ุงู…ุณูƒูŠูˆ ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ู…ูˆุงุฏ ุงู„ู†ุธุฑูŠ ุนู„ุงุฌูŠุงุช ุงุฏูุงู†ุณ ุงู‚ุชุตุงุฏูŠุงุช. TDM DDS ุงู„ุจุงูŠูˆุชูƒู†ูˆู„ุฌูŠ ู…/// ู…ู† ู†ู†ุฒู„ ุดูŠ ูŠู†ุถุงู ุน ุงู„ู‚ูˆุงุฆู… ุญุณุจ ูƒู„ ู…ุงุฏุฉ๐Ÿ‘Œ

45-year-old patient with HER2+ breast cancer received neoadjuvant chemotherapy plus trastuzumab and pertuzumab. At surgery, a residual disease was found. Which agent is most appropriate for adjuvant therapy in this condition ?
Anonymous voting

Salma is a 35 years old women presented to gynecologist seeking for strategies for breast cancer prevention because of her positive family history with BRCA 1 and BRCA2 gene test; The best treatment for risk reduction include:
Anonymous voting

Which genetic mutations significantly incrcase the lifetime risk of breast cancer? a- BRCA1 and BRCA2 b- TPS3 and EGFR c- KRAS and NRAS d- ATM and CHEK2 e- BRCA3 and PALB2 ุฏูˆุฑ ุงูˆู„ 2024 ุทุจุนุง ู‡ุงูŠ ุงู„ุงุณุฆู„ุฉ ุชุฎุต ุงูˆู„ ู…ุญุงุถุฑุฉ ู†ุฒู„ุชู‡ุง ุงู„ูƒู… ุงู„ู…ุญุงุถุฑุฉ ุงู„ุฌุงูŠุฉ ุนู„ุงุฌุงุช ุงู„ breast cancer ุณุคุงู„ ุณู‡ู„ ูˆุญุชู‰ ู…ุชู†ุณูˆู† Breast Cancer ู‡ูˆ BR CA #Breast_Cancer

Drug used to prevent Breast cancer. Which drug increased incidence of endometrial cancer a- Exemestane b- anastrozole c- tamoxifen d- raloxifene e- Letrozole ูˆุฒุงุฑูŠ ุฏูˆุฑ ุงูˆู„ 2024 ุงู„ุญู„ ู…ู† ุงู„ุตูˆุฑุฉ ๐Ÿซ† #Breast_Cancer

A 41 years old woman with a positive family history of breast cancer. What is the treatment of choice to reduce her risk breast cancer risk?
Anonymous voting

A 66 years old woman is suffering from low mineral bone density and strong family history of breast cancer. What would be the best protective agent? #Breast_Cancer
Anonymous voting

ุทู„ุงุจ ุงู„ุฎุงู…ุณุฉ ุงู†ุง ุงู† ุดุงุก ุงู„ู„ู‡ ุงูƒู…ู„ ุงู„ูƒุงู†ุณุฑ ูˆุงุจุฏูŠ ุจุงู„ู†ูุณูŠุฉ ู…ู†ุง ู„ุฐุงูƒ ุงู„ูˆู‚ุช ู‡ูˆุงูŠ ุทู„ุงุจ ุชุฑูŠุฏ ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ู„ู„ู†ูุณูŠุฉ ู ุงู† ุดุงุก ุงู„ู„ู‡ ุงุซู†ุงุก ุดุฑุญูŠ ู„ู„ูƒุงู†ุณุฑ ุฑุญ ุชู†ุฒู„ ุจู‚ูŠุฉ ุงู„ู…ูˆุงุถูŠุน ุจุดูƒู„ ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ุชุจุงุนุง